keyword
MENU ▼
Read by QxMD icon Read
search

Modified vaccinia virus ankara

keyword
https://www.readbyqxmd.com/read/29779454/vaccinia-based-vaccines-to-biothreat-and-emerging-viruses
#1
Les P Nagata, Chad R Irwin, Wei-Gang Hu, David H Evans
The past few years have seen a rash of emerging viral diseases, including the Ebola crisis in West Africa, the pandemic spread of chikungunya, and the recent explosion of Zika in South America. Vaccination is the most reliable and cost-effective method of control of infectious diseases, however, there is often a long delay in production and approval in getting new vaccines to market. Vaccinia was the first vaccine developed for the successful eradication of smallpox and has properties that make it attractive as a universal vaccine vector...
May 21, 2018: Biotechnology & Genetic Engineering Reviews
https://www.readbyqxmd.com/read/29769344/efficient-delivery-of-hcmv-t-cell-antigens-by-attenuated-sendai-virus-vectors
#2
Richard Kiener, Markus Fleischmann, Marian Alexander Wiegand, Niels A W Lemmermann, Christiane Schwegler, Christine Kaufmann, Angelique Renzaho, Simone Thomas, Eva Felder, Hans Helmut Niller, Benedikt Asbach, Ralf Wagner
Human Cytomegalovirus (HCMV) represents a major cause of clinical complications during pregnancy as well as immunosuppression and the licensing of a protective HCMV vaccine remains an unmet global need. Herein, we designed and validated novel Sendai virus (SeV) vectors delivering T cell immunogens IE-1 and pp65. To enhance vector safety, we used a replication-deficient strain (rdSeV) that infects target cells in a non-productive manner while retaining viral gene expression. In this study, we explored the impact that transduction with rdSeV has on human dendritic cells (DCs) by comparing it to the parental, replication-competent Sendai virus strain (rcSeV) as well as the poxvirus strain Modified Vaccinia Ankara (MVA)...
May 16, 2018: Journal of Virology
https://www.readbyqxmd.com/read/29759890/distribution-and-absence-of-generalized-lesions-in-mice-following-single-dose-intramuscular-inoculation-of-the-vaccine-candidate-mva-mers-s
#3
Martin C Langenmayer, Anna-Theresa Lülf-Averhoff, Silvia Adam-Neumair, Robert Fux, Gerd Sutter, Asisa Volz
Modified Vaccinia Virus Ankara (MVA) is a highly attenuated and replication-deficient virus serving as vaccine against infectious diseases. Here, we assessed the in vivo distribution of a recombinant MVA candidate vaccine against the Middle Eastern Respiratory Syndrome (MVA-MERS-S) in mice. Intramuscularly inoculated mice were necropsied at different time points and examined by histology, immunohistochemistry and real-time PCR. We detected inflammation and myonecrosis at the parenteral site and hyperplasia of the draining lymph nodes...
May 11, 2018: Biologicals: Journal of the International Association of Biological Standardization
https://www.readbyqxmd.com/read/29740446/antigenicity-of-leishmania-activated-c-kinase-antigen-lack-in-human-peripheral-blood-mononuclear-cells-and-protective-effect-of-prime-boost-vaccination-with-pci-neo-lack-plus-attenuated-lack-expressing-vaccinia-viruses-in-hamsters
#4
Laura Fernández, Eugenia Carrillo, Lucas Sánchez-Sampedro, Carmen Sánchez, Ana Victoria Ibarra-Meneses, M Angeles Jimenez, Valter Dos Anjos Almeida, Mariano Esteban, Javier Moreno
Leishmania -activated C-kinase antigen (LACK) is a highly conserved protein among Leishmania species and is considered a viable vaccine candidate for human leishmaniasis. In animal models, prime-boost vaccination with LACK-expressing plasmids plus attenuated vaccinia viruses (modified vaccinia Ankara [MVA] and mutant M65) expressing LACK, has been shown to protect against cutaneous leishmaniasis (CL). Further, LACK demonstrated to induce the production of protective cytokines in patients with active CL or cured visceral leishmaniasis, as well as in asymptomatic individuals from endemic areas...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29718990/a-multi-antigenic-mva-vaccine-increases-efficacy-of-combination-chemotherapy-against-mycobacterium-tuberculosis
#5
Stéphane Leung-Theung-Long, Charles-Antoine Coupet, Marie Gouanvic, Doris Schmitt, Aurélie Ray, Chantal Hoffmann, Huguette Schultz, Sandeep Tyagi, Heena Soni, Paul J Converse, Lilibeth Arias, Patricia Kleinpeter, Benoît Sansas, Khisimuzi Mdluli, Cristina Vilaplana, Pere-Joan Cardona, Eric Nuermberger, Jean-Baptiste Marchand, Nathalie Silvestre, Geneviève Inchauspé
Despite the existence of the prophylactic Bacille Calmette-Guérin (BCG) vaccine, infection by Mycobacterium tuberculosis (Mtb) remains a major public health issue causing up to 1.8 million annual deaths worldwide. Increasing prevalence of Mtb strains resistant to antibiotics represents an urgent threat for global health that has prompted a search for alternative treatment regimens not subject to development of resistance. Immunotherapy constitutes a promising approach to improving current antibiotic treatments through engagement of the host's immune system...
2018: PloS One
https://www.readbyqxmd.com/read/29692427/effects-of-pre-existing-orthopoxvirus-specific-immunity-on-the-performance-of-modified-vaccinia-virus-ankara-based-influenza-vaccines
#6
Arwen F Altenburg, Stella E van Trierum, Erwin de Bruin, Dennis de Meulder, Carolien E van de Sandt, Fiona R M van der Klis, Ron A M Fouchier, Marion P G Koopmans, Guus F Rimmelzwaan, Rory D de Vries
The replication-deficient orthopoxvirus modified vaccinia virus Ankara (MVA) is a promising vaccine vector against various pathogens and has an excellent safety record. However, pre-existing vector-specific immunity is frequently suggested to be a drawback of MVA-based vaccines. To address this issue, mice were vaccinated with MVA-based influenza vaccines in the presence or absence of orthopoxvirus-specific immunity. Importantly, protective efficacy of an MVA-based influenza vaccine against a homologous challenge was not impaired in the presence of orthopoxvirus-specific pre-existing immunity...
April 24, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29678552/the-immunogenicity-of-recombinant-vaccines-based-on-modified-vaccinia-ankara-mva-viruses-expressing-african-horse-sickness-virus-vp2-antigens-depends-on-the-levels-of-expressed-vp2-protein-delivered-to-the-host
#7
Eva Calvo-Pinilla, Simon Gubbins, Peter Mertens, Javier Ortego, Javier Castillo-Olivares
African horse sickness (AHS) is a lethal equine disease transmitted by Culicoides biting midges and caused by African horse sickness virus (AHSV). AHS is endemic to sub-Saharan Africa, but devastating outbreaks have been recorded periodically outside this region. The perceived risk of an AHS outbreak occurring in Europe has increased following the frequent epidemics caused in ruminants by bluetongue virus, closely related to AHSV. Attenuated vaccines for AHS are considered unsuitable for use in non-endemic countries due bio-safety concerns...
April 17, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29599502/immunogenicity-and-protection-against-influenza-h7n3-in-mice-by-modified-vaccinia-virus-ankara-vectors-expressing-influenza-virus-hemagglutinin-or-neuraminidase
#8
Clement A Meseda, Vajini Atukorale, Jackeline Soto, Maryna C Eichelberger, Jin Gao, Wei Wang, Carol D Weiss, Jerry P Weir
Influenza subtypes such as H7 have pandemic potential since they are able to infect humans with severe consequences, as evidenced by the ongoing H7N9 infections in China that began in 2013. The diversity of H7 viruses calls for a broadly cross-protective vaccine for protection. We describe the construction of recombinant modified vaccinia virus Ankara (MVA) vectors expressing the hemagglutinin (HA) or neuraminidase (NA) from three H7 viruses representing both Eurasian and North American H7 lineages - A/mallard/Netherlands/12/2000 (H7N3), A/Canada/rv444/2004 (H7N3), and A/Shanghai/02/2013 (H7N9)...
March 29, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29599088/a-single-vaccination-with-non-replicating-mva-at-birth-induces-both-immediate-and-long-term-protective-immune-responses
#9
Cédric Cheminay, Jana Körner, Constanze Bernig, Michael Brückel, Markus Feigl, Martin Schletz, Mark Suter, Paul Chaplin, Ariane Volkmann
Newborns are considered difficult to protect against infections shortly after birth, due to their ineffective immune system that shows quantitative and qualitative differences compared to adults. However, here we show that a single vaccination of mice at birth with a replication-deficient live vaccine Modified Vaccinia Ankara [MVA] efficiently induces antigen-specific B- and T-cells that fully protect against a lethal Ectromelia virus challenge. Protection was induced within 2 weeks and using genetically modified mice we show that this protection was mainly T-cell dependent...
April 25, 2018: Vaccine
https://www.readbyqxmd.com/read/29594879/matrix-m%C3%A2-adjuvant-enhances-immunogenicity-of-both-protein-and-modified-vaccinia-virus-ankara-based-influenza-vaccines-in-mice
#10
Sofia E Magnusson, Arwen F Altenburg, Karin Lövgren Bengtsson, Fons Bosman, Rory D de Vries, Guus F Rimmelzwaan, Linda Stertman
Influenza viruses continuously circulate in the human population and escape recognition by virus neutralizing antibodies induced by prior infection or vaccination through accumulation of mutations in the surface proteins hemagglutinin (HA) and neuraminidase (NA). Various strategies to develop a vaccine that provides broad protection against different influenza A viruses are under investigation, including use of recombinant (r) viral vectors and adjuvants. The replication-deficient modified vaccinia virus Ankara (MVA) is a promising vaccine vector that efficiently induces B and T cell responses specific for the antigen of interest...
March 28, 2018: Immunologic Research
https://www.readbyqxmd.com/read/29519670/heterologous-two-dose-vaccination-with-simian-adenovirus-and-poxvirus-vectors-elicits-long-lasting-cellular-immunity-to-influenza-virus-a-in-healthy-adults
#11
L Coughlan, S Sridhar, R Payne, M Edmans, A Milicic, N Venkatraman, B Lugonja, L Clifton, C Qi, P M Folegatti, A M Lawrie, R Roberts, H de Graaf, P Sukhtankar, S N Faust, D J M Lewis, T Lambe, Avs Hill, S C Gilbert
BACKGROUND: T-cell responses against highly conserved influenza antigens have been previously associated with protection. However, these immune responses are poorly maintained following recovery from influenza infection and are not boosted by inactivated influenza vaccines. We have previously demonstrated the safety and immunogenicity of two viral vectored vaccines, modified vaccinia virus Ankara (MVA) and the chimpanzee adenovirus ChAdOx1 expressing conserved influenza virus antigens, nucleoprotein (NP) and matrix protein-1 (M1)...
March 2018: EBioMedicine
https://www.readbyqxmd.com/read/29514907/distinct-immunogenicity-and-efficacy-of-poxvirus-based-vaccine-candidates-against-ebola-virus-expressing-gp-and-vp40-proteins
#12
Adrián Lázaro-Frías, Sergio Gómez-Medina, Lucas Sánchez-Sampedro, Karl Ljungberg, Mart Ustav, Peter Liljeström, César Muñoz-Fontela, Mariano Esteban, Juan García-Arriaza
Zaire and Sudan ebolavirus species cause a severe disease in humans and nonhuman primates (NHPs) characterized by a high mortality rate. There are no licensed therapies or vaccines against Ebola virus disease (EVD), and the recent 2013 to 2016 outbreak in West Africa highlighted the need for EVD-specific medical countermeasures. Here, we generated and characterized head-to-head the immunogenicity and efficacy of five vaccine candidates against Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV) based on the highly attenuated poxvirus vector modified vaccinia virus Ankara (MVA) expressing either the virus glycoprotein (GP) or GP together with the virus protein 40 (VP40) forming virus-like particles (VLPs)...
June 1, 2018: Journal of Virology
https://www.readbyqxmd.com/read/29474384/development-of-improved-therapeutic-mesothelin-based-vaccines-for-pancreatic-cancer
#13
Michael White, Andrew Freistaedter, Gwendolyn J B Jones, Emmanuel Zervos, Rachel L Roper
Pancreatic cancer is the 5th leading cause of cancer deaths, and there are no effective treatments. We developed a poxvirus platform vaccine with improved immunogenicity and inserted the mesothelin gene to create an anti-mesothelin cancer vaccine. Mesothelin expression is mostly restricted to tumors in adult mammals and thus may be a good target for cancer treatment. We show here that the modified vaccinia virus Ankara (MVA) virus expressing mesothelin and the enhanced MVA virus missing the immunosuppressive A35 gene and expressing mesothelin were both safe in mice and were able to induce IFN-gamma secreting T cells in response to mesothelin expressing tumor cells...
2018: PloS One
https://www.readbyqxmd.com/read/29462200/a-prophylactic-multivalent-vaccine-against-different-filovirus-species-is-immunogenic-and-provides-protection-from-lethal-infections-with-ebolavirus-and-marburgvirus-species-in-non-human-primates
#14
Benoit Callendret, Jort Vellinga, Kerstin Wunderlich, Ariane Rodriguez, Robin Steigerwald, Ulrike Dirmeier, Cedric Cheminay, Ariane Volkmann, Trevor Brasel, Ricardo Carrion, Luis D Giavedoni, Jean L Patterson, Chad E Mire, Thomas W Geisbert, Jay W Hooper, Mo Weijtens, Jutta Hartkoorn-Pasma, Jerome Custers, Maria Grazia Pau, Hanneke Schuitemaker, Roland Zahn
The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV)...
2018: PloS One
https://www.readbyqxmd.com/read/29449630/prime-and-boost-vaccination-elicit-a-distinct-innate-myeloid-cell-immune-response
#15
Jean-Louis Palgen, Nicolas Tchitchek, Jamila Elhmouzi-Younes, Simon Delandre, Inana Namet, Pierre Rosenbaum, Nathalie Dereuddre-Bosquet, Frédéric Martinon, Antonio Cosma, Yves Lévy, Roger Le Grand, Anne-Sophie Beignon
Understanding the innate immune response to vaccination is critical in vaccine design. Here, we studied blood innate myeloid cells after first and second immunization of cynomolgus macaques with the modified vaccinia virus Ankara. The inflammation at the injection site was moderate and resolved faster after the boost. The blood concentration of inflammation markers increased after both injections but was lower after the boost. The numbers of neutrophils, monocytes, and dendritic cells were transiently affected by vaccination, but without any major difference between prime and boost...
February 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29439476/virus-like-vaccines-against-hiv
#16
REVIEW
Anne-Marie C Andersson, Melanie Schwerdtfeger, Peter J Holst
Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV...
February 11, 2018: Vaccines
https://www.readbyqxmd.com/read/29433897/high-cell-density-cultivations-to-increase-mva-virus-production
#17
Daniel Vázquez-Ramírez, Yvonne Genzel, Ingo Jordan, Volker Sandig, Udo Reichl
Increasing the yield and the productivity in cell culture-based vaccine manufacturing using high-cell-density (HCD) cultivations faces a number of challenges. For example, medium consumption should be low to obtain a very high concentration of viable host cells in an economical way but must be balanced against the requirement that accumulation of toxic metabolites and limitation of nutrients have to be avoided. HCD cultivations should also be optimized to avoid unwanted induction of apoptosis or autophagy during the early phase of virus infection...
February 9, 2018: Vaccine
https://www.readbyqxmd.com/read/29425504/functional-cd169-on-macrophages-mediates-interaction-with-dendritic-cells-for-cd8-t-cell-cross-priming
#18
Dieke van Dinther, Henrike Veninga, Salvador Iborra, Ellen G F Borg, Leoni Hoogterp, Katarzyna Olesek, Marieke R Beijer, Sjoerd T T Schetters, Hakan Kalay, Juan J Garcia-Vallejo, Kees L Franken, Lamin B Cham, Karl S Lang, Yvette van Kooyk, David Sancho, Paul R Crocker, Joke M M den Haan
Splenic CD169+ macrophages are located in the marginal zone to efficiently capture blood-borne pathogens. Here, we investigate the requirements for the induction of CD8+ T cell responses by antigens (Ags) bound by CD169+ macrophages. Upon Ag targeting to CD169+ macrophages, we show that BATF3-dependent CD8α+ dendritic cells (DCs) are crucial for DNGR-1-mediated cross-priming of CD8+ T cell responses. In addition, we demonstrate that CD169, a sialic acid binding lectin involved in cell-cell contact, preferentially binds to CD8α+ DCs and that Ag transfer to CD8α+ DCs and subsequent T cell activation is dependent on the sialic acid-binding capacity of CD169...
February 6, 2018: Cell Reports
https://www.readbyqxmd.com/read/29359183/maternal-hiv-1-env-vaccination-for-systemic-and-breast-milk-immunity-to-prevent-oral-shiv-acquisition-in-infant-macaques
#19
Joshua A Eudailey, Maria L Dennis, Morgan E Parker, Bonnie L Phillips, Tori N Huffman, Camden P Bay, Michael G Hudgens, Roger W Wiseman, Justin J Pollara, Genevieve G Fouda, Guido Ferrari, David J Pickup, Pamela A Kozlowski, Koen K A Van Rompay, Kristina De Paris, Sallie R Permar
Mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) contributes to an estimated 150,000 new infections annually. Maternal vaccination has proven safe and effective at mitigating the impact of other neonatal pathogens and is one avenue toward generating the potentially protective immune responses necessary to inhibit HIV-1 infection of infants through breastfeeding. In the present study, we tested the efficacy of a maternal vaccine regimen consisting of a modified vaccinia virus Ankara (MVA) 1086...
January 2018: MSphere
https://www.readbyqxmd.com/read/29343579/identification-of-poxvirus-genome-uncoating-and-dna-replication-factors-with-mutually-redundant-roles
#20
Baoming Liu, Debasis Panda, Jorge D Mendez-Rios, Sundar Ganesan, Linda S Wyatt, Bernard Moss
Genome uncoating is essential for replication of most viruses. For poxviruses, the process is divided into two stages: removal of the envelope allowing early gene expression, and breaching of the core wall allowing DNA release, replication and late gene expression. Subsequent studies showed that the host proteasome and the viral D5 protein, which has an essential role in DNA replication, are required for vaccinia virus (VACV) genome uncoating. In a search for additional VACV uncoating proteins, we noted a report that described a defect in DNA replication and late expression when the gene encoding a 68 kDa ankyrin-repeat/F box protein (68k-ank), associated with the cellular SCF ubiquitin ligase complex, was deleted from the attenuated modified vaccinia virus Ankara (MVA)...
January 17, 2018: Journal of Virology
keyword
keyword
11297
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"